

CURRICULUM VITAE

NAME: Botticelli Andrea

TITLE: Medical Doctor, PhD, assistant professor

EDUCATION

2009 Graduation in Medicine - Sapienza, University of Rome

2010 Medical license acquired. Sapienza, University of Rome

2010 Medical Register in Rome; position: 57700

PROFESSIONAL CAREER

2005-2006 Internship - Division of Molecular Oncology Prof. Gulino, Sapienza, University of Rome

2006-2009 Internship - Division of Medical Oncology - Sant'Andrea Hospital, Rome. Director: Prof. P. Marchetti

Since 2010 School of Specialization in Medical Oncology, Sapienza, University of Rome, 2nd Faculty of Medicine- Sant'Andrea Hospital, Rome

20.05.2015 Specialization in Medical Oncology, Sapienza, University of Rome
"Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort." Prof. Paolo Marchetti

2015-2018 PhD Sapienza, University of Rome. "Measurement of Circulating free DNA in advanced breast cancer patients treated with Exemestane + Everolimus."

COORDINATOR AND TEACHER IMMUNO-ONCOLOGY MASTER II LEVEL, Sapienza, University of Rome

since 2016 Assistant Professor (RTDA) , Clinical and Molecular Department, Sapienza, University of Rome, and medical doctor at Policlinico Umberto I, Rome (from 2 January 2019)

since May 2018

WINNER : PREMIO ATENEO, SAPIENZA UNIVERSITY OF Rome : avvio alla ricerca 2016-2017

Winner: Preceptorship ESMO, Immuno-Oncology Congresso 29 September -1 October 2016

Since 2020 TEACHER in doctoral school in “network medicine and precision oncology”

MOST RECENT PUBLICATIONS

1 La Torre M, Mazzuca F, Ferri M, Mari FS, Botticelli A, Pillozzi E, Lorenzon L, Osti MF, Marchetti P, Enrici RM, Ziparo V

The importance of lymph node retrieval and lymph node ratio following preoperative chemoradiation of rectal cancer.

Colorectal Dis. 2013 Jul;15(7):e382-8. doi: 10.1111/codi.12242.

IF 2.017

2 Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli E.

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study.

Clinicoecon Outcomes Res. 2013 Apr 11;5:125-35. doi: 10.2147/CEOR.S41850. Print 2013.

3 Botticelli A, De Francesco GP, Di Stefano D.

Breast metastasis from clear cell renal cell carcinoma.

J Ultrasound. 2013 Jul 5;16(3):127-30. doi: 10.1007/s40477-013-0026-9. eCollection 2013 Jul 5.

4 La Torre M, Nigri G, Mazzuca F, Ferri M, Botticelli A, Lorenzon L, Pillozzi E, Ziparo V.

Standard versus limited colon resection for high risk T1 colon cancer. A matched case-control study.

J Gastrointest Liver Dis. 2014 Sep;23(3):285-90. doi: 10.15403/jgld.2014.1121.233.mlt.

IF 2.195

5 Mercantini P, Lorenzon L, Tarantino G, Balducci G, Ferri M, Mazzuca F, Botticelli A, Marchetti P.

Electrochemotherapy treatment of cutaneous metastases from breast cancer.

Am Surg. 2015 May;81(5):E222-5.

IF 0.531

6 Botticelli A, Mazzotti E, Di Stefano D, Petrocelli V, Mazzuca F, La Torre M, Ciabatta FR, Giovagnoli RM, Marchetti P, Bonifacino A.

Positive impact of elastography in breast cancer diagnosis: an institutional experience.

J Ultrasound. 2015 Aug 12;18(4):321-7. doi: 10.1007/s40477-015-0177-y. eCollection 2015 Dec.

7 Botticelli A, Mazzuca F, Borro M, Mazzotti E, La Torre M, Bonifacino A, Ciabatta FR, Gentile G, Maddalena C, Simmaco M, Marchetti P.

FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?

World J Oncol. 2015 Oct;6(5):437-440. doi: 10.14740/wjon934w. Epub 2015 Oct 26.

8 Mazzuca F, Borro M, Botticelli A, Aimati L, Gentile G, Capalbo C, Maddalena C, Mazzotti E, Simmaco M, Marchetti P.

Effect of MTHFR Polymorphisms on Gastrointestinal Cancer Risk in Italy.

World J Oncol. 2015 Aug;6(4):394-397. doi: 10.14740/wjon930w. Epub 2015 Aug 27.

9 Botticelli A, Borro M, Onesti CE, Strigari L, Gentile G, Cerbelli B, Romiti A, Occhipinti M, Sebastiani C, Lionetto L, Marchetti L, Simmaco M, Marchetti P, Mazzuca F.

Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?

PLoS One. 2016 Sep 22;11(9):e0163105. doi: 10.1371/journal.pone.0163105. eCollection 2016.

IF 3.1

10 Romiti A, Roberto M, D'Antonio C, Onesti CE, Barucca V, Milano A, Gentile G, Lionetto L, Medda E, Mazzuca F, Botticelli A, Falcone R, Simmaco M, Marchetti P.

The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer.

Anticancer Drugs. 2016 Nov;27(10):1044-9. doi: 10.1097/CAD.0000000000000429.

IF 2.320

11 Mazzuca F, Botticelli A, Mazzotti E, La Torre M, Borro M, Marchetti L, Maddalena C, Gentile G, Simmaco M, Marchetti P.

CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy.

Eurasian J Med. 2016 Feb;48(1):10-4. doi: 10.5152/eurasianjmed.2015.008. Epub 2015 Jul 7.

12 Mazzuca F, Borro M, Botticelli A, Mazzotti E, Marchetti L, Gentile G, La Torre M, Lionetto L, Simmaco M, Marchetti P.

Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort.

Oncotarget. 2016 Apr 12;7(15):20612-20. doi: 10.18632/oncotarget.7991.

IF 5.168

13 Gentile G, Botticelli A, Lionetto L, Mazzuca F, Simmaco M, Marchetti P, Borro M.

Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction.

Pharmacogenomics J. 2016 Aug;16(4):320-5. doi: 10.1038/tpj.2015.56. Epub 2015 Jul 28.

IF 3.815

14 Ghidini M, Tomasello G, Botticelli A, Barni S, Zabbialini G, Seghezzi S, Passalacqua R, Braconi C, Petrelli F.

Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis.

HPB (Oxford). 2017 Sep;19(9):741-748. doi: 10.1016/j.hpb.2017.05.010. Epub 2017 Jul 3. Review.

IF3.131

15 Sini V, Botticelli A, Lunardi G, Gori S, Marchetti P.

Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.

Pharmacogenomics. 2017 Jun;18(8):821-830. doi: 10.2217/pgs-2017-0006. Epub 2017 Jun 8. Review.

IF 3.812

16 Angelini S, Botticelli A, Onesti CE, Giusti R, Sini V, Durante V, Strigari L, Gentile G, Cerbelli B, Pellegrini P, Sgroi V, Occhipinti M, Di Pietro FR, Rossi A, Simmaco M, Mazzuca F, Marchetti P.

Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.

Anticancer Res. 2017 May;37(5):2633-2639.

IF 1.865

17 Botticelli A, Onesti CE, Strigari L, Occhipinti M, Di Pietro FR, Cerbelli B, Petremolo A, Anselmi E, Macrini S, Roberto M, Falcone R, Lionetto L, Borro M, Milano A, Gentile G, Simmaco M, Marchetti P, Mazzuca F.

A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient.

Anticancer Drugs. 2017 Jun;28(5):551-556. doi: 10.1097/CAD.0000000000000492.

IF 1.869

18 Roberto M, Romiti A, Botticelli A, Mazzuca F, Lionetto L, Gentile G, Paris I, Falcone R, Bassanelli M, Di Pietro FR, Onesti CE, Anselmi E, Macrini S, Simmaco M, Marchetti P.

Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.

Eur J Clin Pharmacol. 2017 Feb;73(2):157-164. doi: 10.1007/s00228-016-2160-8. Epub 2016 Nov 18.

IF 2.679

19 Onesti CE, Botticelli A, La Torre M, Borro M, Gentile G, Romiti A, Lionetto L, Petremolo A, Occhipinti M, Roberto M, Falcone R, Simmaco M, Marchetti P, Mazzuca F.

5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.

Anticancer Drugs. 2017 Mar;28(3):322-326. doi: 10.1097/CAD.0000000000000453.

IF 1.869

20 Botticelli A, Zizzari I, Mazzuca F, Ascierio PA, Putignani L, Marchetti L, Napoletano C, Nuti M, Marchetti P.

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment.

Oncotarget. 2017 Jan 31;8(5):8890-8899. doi: 10.18632/oncotarget.12985. Review.

IF 5.168

21 Borro M, Botticelli A, Mazzuca F, Onesti EC, Gentile G, Romiti A, Cerbelli B, Mazzotti E, Marchetti L, Lionetto L, Simmaco M, Marchetti P.

Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer.

Oncotarget. 2017 Feb 21;8(8):14050-14057. doi: 10.18632/oncotarget.12571.

IF 5.168

22 Cerbelli B, Pernazza A, Botticelli A, Fortunato L, Monti M, Sciattella P, Campagna D, Mazzuca F, Mauri M, Naso G, Marchetti P, d'Amati G, Costarelli L.

PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?

Biomed Res Int. 2017;2017:1750925. doi: 10.1155/2017/1750925. Epub 2017 Dec 14.

IF 2.583

23 Pizzuti L, Sergi D, Sperduti I, Lauro LD, Mazzotta M, Botti C, Izzo F, Marchetti L, Tomao S, Marchetti P, Natoli C, Grassadonia A, Gamucci T, Mentuccia L, Magnolfi E, Vaccaro A, Cassano A, Rossi E, Botticelli A, Sini V, Sarobba MG, Fabbri MA, Moscetti L, Astone A, Michelotti A, De Angelis C, Bertolini I, Angelini F, Ciliberto G, Maugeri-Saccà M, Giordano A, Barba M, Vici P.

Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.

Cancer Biol Ther. 2018 Apr 3;19(4):328-334. doi: 10.1080/15384047.2017.1416938. Epub 2018 Feb 16.

IF 2.879

24 Roberto M, Falcone R, Mazzuca F, Archibugi L, Castaldi N, Botticelli A, Osti MF, Marchetti P.

The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression.

Medicine (Baltimore). 2017 Dec;96(48):e9023. doi: 10.1097/MD.0000000000009023.

IF 2.028

25 Occhipinti M, Falcone R, Onesti CE, Botticelli A, Mazzuca F, Marchetti P, Lauro S.

Crizotinib plus radiotherapy in brain oligoprogressive NSCLC *ROS1* rearranged and PD-L1 strong.

J Thorac Dis. 2017 Nov;9(11):E985-E989. doi: 10.21037/jtd.2017.09.74.

26 Botticelli A, Onesti CE, Zizzari I, Cerbelli B, Sciattella P, Occhipinti M, Roberto M, Di Pietro F, Bonifacino A, Ghidini M, Vici P, Pizzuti L, Napoletano C, Strigari L, D'Amati G, Mazzuca F, Nuti M, Marchetti P.

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

Oncotarget. 2017 Nov 1;8(59):99336-99346. doi: 10.18632/oncotarget.22242. eCollection 2017 Nov 21.

IF 5.168

27 Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, Magnolfi E, Iezzi L, Moscetti L, Fabbri A, Cassano A, Grassadonia A, Omarini C, Piacentini F, Botticelli A, Bertolini I, Scinto AF, Zampa G, Mauri M, D'Onofrio L, Sini V, Barba M, Maugeri-Saccà M, Rossi E, Landucci E, Tomao S, Alberti AM, Giotta F, Ficorella C, Adamo V, Russo A, Lorusso V, Cannita K, Barni S, Laudadio L, Greco F, Garrone O, Della Giulia M, Marolla P, Sanguineti G, Di Cocco B, Ciliberto G, De Maria R, Gamucci T. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience.

Oncotarget. 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176. eCollection 2017 Aug 22.

IF5.168

28 Pizzuti L, Marchetti P, Natoli C, Gamucci T, Santini D, Scinto AF, Iezzi L, Mentuccia L, D'Onofrio L, Botticelli A, Moscetti L, Sperati F, Botti C, Ferranti F, Buglioni S, Sanguineti G, Di Filippo S, di Lauro L, Sergi D, Catenaro T, Tomao S, Giordano A, Maugeri-Saccà M, Barba M, Vici P.

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study.

Sci Rep. 2017 Sep 6;7(1):10597. doi: 10.1038/s41598-017-10061-2.

IF 4.122

29 Botticelli A, Cerbelli B, Lionetto L, Zizzari I, Salati M, Pisano A, Federica M, Simmaco M, Nuti M, Marchetti P.

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

J Transl Med. 2018 Aug 6;16(1):219. doi: 10.1186/s12967-018-1595-3.

IF4.098

30 Nuti M, Zizzari IG, Botticelli A, Rughetti A, Marchetti P.

The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one.

Cancer Treat Rev. 2018 Nov;70:41-46. doi: 10.1016/j.ctrv.2018.07.016. Epub 2018 Jul 26. Review.

IF8.332

31 Roberto M, Botticelli A, Strigari L, Ghidini M, Onesti CE, Ratti M, Benzoni I, Pizzo C, Falcone R, Lomiento D, Donida BM, Totaro L, Mazzuca F, Marchetti P.

Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival.

Med Oncol. 2018 Jun 19;35(7):111. doi: 10.1007/s12032-018-1166-8.

IF 3.252

32 Mazzuca F, Onesti CE, Roberto M, Di Girolamo M, Botticelli A, Begini P, Strigari L, Marchetti P, Muscaritoli M.
Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines.
Oncotarget. 2018 May 22;9(39):25714-25722. doi: 10.18632/oncotarget.25394. eCollection 2018 May 22.
IF 5.168

33 Salati M, Baldessari C, Cerbelli B, Botticelli A.
Nivolumab in pretreated non-small cell lung cancer: continuing the immunolotion.
Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S91-S94. doi: 10.21037/tlcr.2018.01.14. No abstract available.

34 Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, Ruscito I, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M.
TK Inhibitor Pazopanib Primes DCs by Downregulation of the β -Catenin Pathway.
Cancer Immunol Res. 2018 Jun;6(6):711-722. doi: 10.1158/2326-6066.CIR-17-0594. Epub 2018 Apr 26.
IF 8.7

35 Milano A, Mazzetta F, Valente S, Ranieri D, Leone L, Botticelli A, Onesti CE, Lauro S, Raffa S, Torrisi MR, Marchetti P.
Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice.
Anal Cell Pathol (Amst). 2018 Feb 27;2018:3506874. doi: 10.1155/2018/3506874. eCollection 2018.
IF 1.788

36 Nuti, m., zizzari, i.g., botticelli, a., putignani, l., marchetti, p.
the microbiota impact: bacteria shaping immunity, disease and response to therapy
translational cancer research, 2018, 7, pp. S616–s619
IF1.07

37 Gamucci T, Pizzuti L, Sperduti I, Mentuccia L, Vaccaro A, Moscetti L, Marchetti P, Carbognin L, Michelotti A, Iezzi L, Cassano A, Grassadonia A, Astone A, Botticelli A, Magnolfi E, Di Lauro L, Sergi D, Fuso P, Tinari N, Barba M, Maugeri-Saccà M, Landucci E, Conti F, Sanguineti G, De Tursi M, lafrate G, Giordano A, Ciliberto G, Natoli C, Vici P.
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
J Cell Physiol. 2018 Mar;233(3):2313-2323. doi: 10.1002/jcp.26103. Epub 2017 Sep 27.
IF 4.522

38 Ghidini M, Pizzo C, Botticelli A, Hahne JC, Passalacqua R, Tomasello G, Petrelli F.
Biliary tract cancer: current challenges and future prospects.
Cancer Manag Res. 2018 Dec 28;11:379-388. doi: 10.2147/CMAR.S157156. eCollection 2019. Review.
IF 2.886

39 Cortellini A, Vitale MG, De Galitiis F, Di Pietro FR, Berardi R, Torniai M, De Tursi M, Grassadonia A, Di Marino P, Santini D, Zeppola T, Anesi C, Gelibter A, Occhipinti MA, Botticelli A, Marchetti P, Rastelli F, Pergolesi F, Tudini M, Silva RR, Mallardo D, Vanella V, Ficorella C, Porzio G, Ascierto PA Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.
J Transl Med. 2019 Nov 15;17(1):376. doi: 10.1186/s12967-019-02132-x.
IF 4.124

40 Salati M, Baldessari C, Bonetti LR, Messina C, Merz V, Cerbelli B, Botticelli A.
NUT midline carcinoma: Current concepts and future perspectives of a novel tumour entity.
Crit Rev Oncol Hematol. 2019 Dec;144:102826. doi: 10.1016/j.critrevonc.2019.102826. Epub 2019 Nov 1. Review.
IF 5.833

41 Rossi A, Roberto M, Panebianco M, Botticelli A, Mazzuca F, Marchetti P. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
Eur J Pharmacol. 2019 Nov 5;862:172621. doi: 10.1016/j.ejphar.2019.172621. Epub 2019 Aug 22. Review.
IF 3.263

42 Mazzuca F, Roberto M, Arrivi G, Sarfati E, Schipilliti FM, Crimini E, Botticelli A, Di Girolamo M, Muscaritoli M, Marchetti P.
Clinical Impact of Highly Purified, Whey Proteins in Patients Affected With Colorectal Cancer Undergoing Chemotherapy: Preliminary Results of a Placebo-Controlled Study.
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419866920. doi: 10.1177/1534735419866920.
IF 2.379

43 Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D,

Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, Vici P.

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.

Int J Cancer. 2019 Jul 22. doi: 10.1002/ijc.32583.

IF 5.145

44 Michela Roberto , Andrea Botticelli , Fabiana Cecere , Francesco Cognetti , Raffaele Giusti , Alain Gelibter , Antonio Lugini , Fabrizio Nelli , Marianna Nuti , Daniele Santini , Paolo Marchetti

Immunotherapy in non-small cell lung cancer patients: back to the future | L'immunoterapia nel tumore del polmone non a piccole cellule: ritorno al futuro

Recenti progressi in medicina, 2019, 110(12), pp. 587–593

45 Giusti R, Scarpi E, Cannita K, Silva RR, Filetti M, Mazzotta M, Ficorella C, Botticelli A, Maltoni M, Marchetti P, Porzio G, Verna L.

Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors.

Support Care Cancer. 2019 Jun 8. doi: 10.1007/s00520-019-04905-y.

IF 2.635

46 Sacchetti B, Botticelli A, Pierelli L, Nuti M, Alimandi M.

CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy.

Int J Mol Sci. 2019 Apr 17;20(8). pii: E1903. doi: 10.3390/ijms20081903. Review.

IF 4.556

47 Falcone R, Romiti A, Filetti M, Roberto M, Righini R, Botticelli A, Pillozzi E, Ghidini M, Pizzo C, Mazzuca F, Marchetti P.

Impact of tumor site on the prognosis of small bowel adenocarcinoma.

Tumori. 2019 Apr 1;300891619839297. doi: 10.1177/0300891619839297.

IF 1.707

48 Botticelli A, Salati M, Di Pietro FR, Strigari L, Cerbelli B, Zizzari IG, Giusti R, Mazzotta M, Mazzuca F, Roberto M, Vici P, Pizzuti L, Nuti M, Marchetti P.

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.

J Transl Med. 2019 Mar 27;17(1):99. doi: 10.1186/s12967-019-1847-x.

IF 4.124

49 Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierto PA, Ficorella C, Natoli C.

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.

J Immunother Cancer. 2019 Feb 27;7(1):57. doi: 10.1186/s40425-019-0527-y.

IF 4.110

50 Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A, Brocco D, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Sabbatini R, Bracarda S, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, Iacono D, Migliorino MR, Rossi A, Porzio G, Cannita K, Ciciarelli V, Fargnoli MC, Ascierto PA, Ficorella C.

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.

Oncologist. 2019 Jun;24(6):e327-e337. doi: 10.1634/theoncologist.2018-0618. Epub 2019 Feb 22.

IF 5.025

51 Cerbelli B, Botticelli A, Pisano A, Campagna D, De Vincentiis L, Pernazza A, Frusone F, Scavina P, Monti M, Fortunato L, Costarelli L, d'Amati G.

Breast cancer subtypes affect the nodal response after neoadjuvant chemotherapy in locally advanced breast cancer: Are we ready to endorse axillary conservation?

Breast J. 2019 Mar;25(2):273-277. doi: 10.1111/tbj.13206. Epub 2019 Feb 7.

IF 1.991

52 Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L,

Iezzi L, Mentuccia L, Fabbri A, Barba M, Sanguineti G, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Aroldi F, Orlandi A, Moscetti L, Sergi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L, De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamagni C, Rubino D, Cortesi E, Magri V, Pomati G, Scagnoli S, Capomolla E, Kayal R, Scinto AF, Corsi D, Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carbognin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficorella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, Vici P. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.

J Cell Physiol. 2019 Jun;234(6):7708-7717. doi: 10.1002/jcp.27832. Epub 2018 Dec 10.

IF 5.546

53 Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, Barba M, Sergi D, Iezzi L, Maugeri-Saccà M, Vaccaro A, Magnolfi E, Gelibter A, Barchiesi G, Magri V, D'Onofrio L, Cassano A, Rossi E, Botticelli A, Moscetti L, Omarini C, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Mazzotta M, Bria E, Foglietta J, Samaritani R, Garufi C, Mariani L, Barni S, Mirabelli R, Sarmiento R, Graziano V, Santini D, Marchetti P, Tonini G, Di Lauro L, Sanguineti G, Paoletti G, Tomao S, De Maria R, Veltri E, Paris I, Giotta F, Latorre A, Giordano A, Ciliberto G, Vici P.

A multicenter RETrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.

Cancer Biol Ther. 2019;20(2):192-200. doi: 10.1080/15384047.2018.1523095. Epub 2018 Nov 7.

IF 3.659

54 Cerbelli B, Botticelli A, Pisano A, Pernazza A, Campagna D, De Luca A, Ascierio PA, Pignataro MG, Pelullo M, Rocca CD, Marchetti P, Fortunato L, Costarelli L, d'Amati G CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer. Virchows Arch. 2020 Apr;476(4):569-576. doi: 10.1007/s00428-019-02722-6. Epub 2019 Dec 18. PMID: 31853625

IF2.906

55 Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, Marconcini R, Russano M, Zeppola T, Anesi C, Filetti M, Marchetti P, Botticelli A, Gelibter A, De Galitiis F, Vitale MG, Rastelli F, Tudini M, Silva RR, Atzori F, Chiari R, Ricciuti B, De Giglio A, Migliorino MR, Mallardo D, Vanella V, Mosillo C, Bracarda S, Rinaldi S, Berardi R, Natoli C, Ficorella C, Porzio G, Ascierio PA Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. Eur J Cancer. 2020 Mar;128:17-26. doi: 10.1016/j.ejca.2019.12.031. Epub 2020 Mar 5. PMID: 32109847

IF 7.275

56 Nigro O, Pinotti G, De Galitiis F, Di Pietro FR, Giusti R, Filetti M, Bersanelli M, Lazzarin A, Bordi P, Catino A, Pizzuttilo P, Galetta D, Marchetti P, Botticelli A, Scagnoli S, Russano M, Santini D, Torniai M, Berardi R, Ricciuti B, De Giglio A, Chiari R, Russo A, Adamo V, Tudini M, Silva RR, Bolzacchini E, Giordano M, Di Marino P, De Tursi M, Rijavec E, Ghidini M, Vallini I, Stucci LS, Tucci M, Pala L, Conforti F, Queirolo P, Tanda E, Spagnolo F, Cecchi F, Bracarda S, Macrini S, Santoni M, Battelli N, Fargnoli MC, Porzio G, Tuzi A, Suter MB, Ficorella C, Cortellini A. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.

Eur J Cancer. 2020 Jul;134:19-28. doi: 10.1016/j.ejca.2020.04.025. Epub 2020 May 23. PMID: 32454395

IF 7.275

57 Marinelli D, Mazzotta M, Scalera S, Terrenato I, Sperati F, D'Ambrosio L, Pallocca M, Corleone G, Krasniqi E, Pizzuti L, Barba M, Carpano S, Vici P, Filetti M, Giusti R, Vecchione A, Occhipinti M, Gelibter A, Botticelli A, De Nicola F, Ciuffreda L, Goeman F, Gallo E, Visca P, Pescarmona E, Fanciulli M, De Maria R, Marchetti P, Ciliberto G, Maugeri-Saccà M KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. Ann Oncol. 2020 Dec;31(12):1746-1754. doi: 10.1016/j.annonc.2020.08.2105. Epub 2020 Aug 28. PMID: 32866624

IF 18.274

58 Marchetti P, Botticelli A, Ascierio AP, Curigliano G, Giannarelli D. Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis.

J Transl Med. 2020 Nov 25;18(1):446. doi: 10.1186/s12967-020-02588-2. PMID: 33239030

IF 4.124

59 Gianluca Tenore , Alessandro Nuvoli , Ahmed Mohsen , Andrea Cassoni , Andrea Battisti, Valentina Terenzi ,Marco Della Monaca , Ingrid Raponi , Edoardo Brauner , Francesca De Felice, Daniela Musio, Cira Rosaria Tiziana Di Gioia , Daniela Messineo, Silvia Mezi, Stefano Di Carl, Andrea Botticelli, Valentino Valentini , Paolo Marchetti , Vincenzo Tombolini , Marco De Vincentiis, Antonella Polimeni and Umberto Romeo Tobacco, Alcohol and Family History of Cancer as Risk Factors of Oral Squamous Cell Carcinoma: Case-Control Retrospective Study *Applied Sciences (Switzerland)*, 2020, 10(11), 3896

IF 2.474

60 Grizzi G, Ghidini M, Botticelli A, Tomasello G, Ghidini A, Grossi F, Fusco N, Cabiddu M, Savio T, Petrelli F. Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options.

Cancer Manag Res. 2020 Jan 30;12:675-686. doi: 10.2147/CMAR.S202965. eCollection 2020.PMID: 32099464
IF 2.886

61 Botticelli A, Vernocchi P, Marini F, Quagliariello A, Cerbelli B, Reddel S, Del Chierico F, Di Pietro F, Giusti R, Tomassini A, Giampaoli O, Miccheli A, Zizzari IG, Nuti M, Putignani L, Marchetti P Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment..J Transl Med. 2020 Feb 3;18(1):49. doi: 10.1186/s12967-020-02231-0.PMID: 32014010
IF 4.124

62 Ralli M, Botticelli A, Visconti IC, Angeletti D, Fiore M, Marchetti P, Lambiase A, de Vincentiis M, Greco A Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. J Immunol Res. 2020 Jun 28;2020:9235638. doi: 10.1155/2020/9235638. eCollection 2020.PMID: 32671117
IF 3.327

63 Botticelli A, Cirillo A, Scagnoli S, Cerbelli B, Strigari L, Cortellini A, Pizzuti L, Vici P, De Galitiis F, Di Pietro FR, Cerbelli E, Ghidini M, D'Amati G, Della Rocca C, Mezi S, Gelibter A, Giusti R, Cortesi E, Ascierto PA, Nuti M, Marchetti P.The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.Vaccines (Basel). 2020 Apr 28;8(2):203. doi: 10.3390/vaccines8020203.PMID: 32353934
IF 3.1

64 De Luca A, Tripodi D, Frusone F, Leonardi B, Cerbelli B, Botticelli A, Vergine M, D'Andrea V, Pironi D, Sorrenti S, Amabile MI.Retrospective Evaluation of the Effectiveness of a Synthetic Glue and a Fibrin-Based Sealant for the Prevention of Seroma Following Axillary Dissection in Breast Cancer Patients.Front Oncol. 2020 Jul 17;10:1061. doi: 10.3389/fonc.2020.01061. eCollection 2020.PMID: 32766138
IF 4.416

65 Botticelli A, Scagnoli S, Roberto M, Lionetto L, Cerbelli B, Simmaco M, Marchetti P.5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine. J Oncol Pharm Pract. 2020 Dec;26(8):1836-1842. doi: 10.1177/1078155220904999. Epub 2020 Mar 4.PMID: 32131682
IF 1.850

66 Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Bisonni R, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Bareggi C, Nigro O, Tuzi A, De Tursi M, Petraghani N, Pala L, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Pinato DJ, Porzio G, Ficorella C, Ascierto PA.Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. J Immunother Cancer. 2020 Nov;8(2):e001361. doi: 10.1136/jitc-2020-001361.PMID: 33154150
IF 4.110

67 Vernocchi P, Gili T, Conte F, Del Chierico F, Conta G, Miccheli A, Botticelli A, Paci P, Caldarelli G, Nuti M, Marchetti P, Putignani L Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked Biomarkers in Patients Affected by Non-Small Cell Lung Cancer. Int J Mol Sci. 2020 Nov 19;21(22):8730. doi: 10.3390/ijms21228730.PMID: 33227982
IF 4.556

68 Marinelli D, Mazzotta M, Pizzuti L, Krasniqi E, Gamucci T, Natoli C, Grassadonia A, Tinari N, Tomao S, Sperduti I, Sanguineti G, Botticelli A, Fabbri A, Botti C, Ciliberto G, Barba M, Vici P Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials. Cancers (Basel). 2020 Sep 3;12(9):2497. doi: 10.3390/cancers12092497.PMID: 32899209
IF 5.742

69 Botticelli A, Mezi S, Pomati G, Cerbelli B, Cerbelli E, Roberto M, Giusti R, Cortellini A, Lionetto L, Scagnoli S, Zizzari IG, Nuti M, Simmaco M, Marchetti P.Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1. Front Immunol. 2020 Jul 7;11:1243. doi: 10.3389/fimmu.2020.01243. eCollection 2020.PMID: 32733441
5.085

70 Cerbelli B, Scagnoli S, Mezi S, De Luca A, Pisegna S, Amabile MI, Roberto M, Fortunato L, Costarelli L, Pernazza A, Strigari L, Della Rocca C, Marchetti P, d'Amati G, Botticelli A.Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer. Cancers (Basel). 2020 Sep 16;12(9):2648. doi: 10.3390/cancers12092648.PMID: 32947953
IF 5.742

71 Krasniqi E, Pizzuti L, Barchiesi G, Sergi D, Carpano S, Botti C, Kayal R, Sanguineti G, Marchetti P, Botticelli A, Marinelli D, Gamucci T, Natoli C, Grassadonia A, Tinari N, Tomao S, Tonini G, Santini D, Michelotti A, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Cazzaniga M, Moschetti L, Fabbri A, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Garufi C, Di Stefano P, Mirabelli R,

Veltri E, Paris I, Giotta F, Lorusso V, Landucci E, Ficorella C, Roselli M, Adamo V, Ricciardi G, Russo A, Valerio MR, Berardi R, Pistelli M, Cannita K, Zamagni C, Garrone O, Baldini E, Livi L, Meattini I, Del Medico P, Generali D, De Maria R, Risi E, Ciliberto G, Villa A, Sperduti I, Mazzotta M, Barba M, Giordano A, Vici P. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.

J Cell Physiol. 2020 Nov;235(11):7900-7910. doi: 10.1002/jcp.29445. Epub 2020 Jan 15. PMID: 31943171
IF 5.546

72 Botticelli A, Mezi S, Pomati G, Cerbelli B, Di Rocco C, Amirhassankhani S, Sirgiovanni G, Occhipinti M, Napoli V, Emiliani A, Mazzuca F, Tomao S, Nuti M, Marchetti P. The 5-Whs of immunotherapy in head and neck cancer.

Crit Rev Oncol Hematol. 2020 Sep;153:103041. doi: 10.1016/j.critrevonc.2020.103041. Epub 2020 Jun 30. PMID: 32629362 Review.
IF 5.833

73 Mezi S, Pomati G, Botticelli A, Roberto M, Cerbelli B, Cirillo A, Di Gioia C, Corsi A, Vullo F, De Vincentiis M, Polimeni A, Tombolini V, Valentini V, Marchetti P. Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experience. Anticancer Drugs. 2020 Nov;31(10):1074-1083. doi: 10.1097/CAD.0000000000000977. PMID: 32932276
IF 2.260

74 Ugolini A, Zizzari IG, Ceccarelli F, Botticelli A, Colasanti T, Strigari L, Rughetti A, Rahimi H, Conti F, Valesini G, Marchetti P, Nuti M. IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137⁺T-cells. EBioMedicine. 2020 Dec;62:103098. doi: 10.1016/j.ebiom.2020.103098. Epub 2020 Nov 6. PMID: 33166793
IF 5.736

75 Orlandi A, Iattoni E, Pizzuti L, Fabbri A, Botticelli A, Di Dio C, Palazzo A, Garufi G, Indelicati G, Alesini D, Carbognin L, Paris I, Vaccaro A, Moscetti L, Fabi A, Magri V, Naso G, Cassano A, Vici P, Giannarelli D, Franceschini G, Marchetti P, Bria E, Tortora G. Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series.

J Pers Med. 2020 Dec 18;10(4):291. doi: 10.3390/jpm10040291. PMID: 33353132
IF 2.318

76 Vici P, Pizzuti L, Krasniqi E, Botticelli A, Ciliberto G, Barba M. Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors.

Immunotherapy. 2020 Jul;12(10):675-679. doi: 10.2217/imt-2020-0142. Epub 2020 Jun 3. PMID: 32489118
IF 2.964

77 Zizzari IG, Di Filippo A, Scirocchi F, Di Pietro FR, Rahimi H, Ugolini A, Scagnoli S, Vernocchi P, Del Chierico F, Putignani L, Rughetti A, Marchetti P, Nuti M, Botticelli A, Napoletano C. Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients. J Pers Med. 2020 Nov 4;10(4):208. doi: 10.3390/jpm10040208. PMID: 33158018
IF 2.318

78 De Felice F, Valentini V, de Vincentiis M, Catalano C, Musio D, Mezi S, Messineo D, Di Gioia CRT, Tenore G, Priore P, Ralli M, Vullo F, Botticelli A, Brauner E, Giovannetti F, Greco A, Romeo U, Marchetti P, Della Rocca C, Polimeni A, Tombolini V. Phase 2 of coronavirus disease (COVID-19) and head and neck cancer: An action plan. Oral Dis. 2020 Jul 29. doi: 10.1111/odi.13576. Online ahead of print. PMID: 32930434 No abstract available.
IF 2.613

79 Di Prima A, Botticelli A, Scalzulli E, Colafigli G, Pepe S, Lisi C, Marchetti P, Martelli M, Foà R, Breccia M. Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab.

Ann Hematol. 2020 Aug 27. doi: 10.1007/s00277-020-04236-7. Online ahead of print. PMID: 32856142
IF 2.904

80 Ceccarelli F, Botticelli A, Gelibter AJ, Leccese I, Lucchetti R, Cortesi E, Valesini G, Marchetti P, Conti F. 'Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation' by Braaten *et al*: another point of view. Ann Rheum Dis. 2020 Jan 6;annrheumdis-2019-216867. doi: 10.1136/annrheumdis-2019-216867. Online ahead of print. PMID: 31907163 No abstract available.
IF 16.102

81 Roberto M, Marchetti P, Arrivi G, Di Pietro FR, Cascinu S, Gelsomino F, Caputo F, Cerma K, Ghidini M, Ratti M, Pizzo C, Ficorella C, Parisi A, Cortellini A, Urbano F, Calandrella ML, Botticelli A, Dell'Aquila E, Minelli A, Fulgenzi C, Montori A, Pilozi E, Mazzuca F. The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference.

Int J Colorectal Dis. 2020 Aug;35(8):1513-1527. doi: 10.1007/s00384-020-03589-9. Epub 2020 May 7. PMID: 32382835
IF 2.108

82 Zizzari IG, Napoletano C, Di Filippo A, Botticelli A, Gelibter A, Calabrò F, Rossi E, Schinzari G, Urbano F, Pomati G, Scagnoli S, Rughetti A, Caponnetto S, Marchetti P, Nuti M Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma.
.Cancers (Basel). 2020 Sep 14;12(9):2620. doi: 10.3390/cancers12092620.PMID: 32937860
IF 5.742

83 Mazzotta M, Filetti M, Occhipinti M, Marinelli D, Scalera S, Terrenato I, Sperati F, Pallocca M, Rizzo F, Gelibter A, Botticelli A, Scafetta G, Di Napoli A, Krasniqi E, Pizzuti L, Barba M, Carpano S, Vici P, Fanciulli M, De Nicola F, Ciuffreda L, Goeman F, De Maria R, Vecchione A, Giusti R, Ciliberto G, Marchetti P, Maugeri-Saccà M.Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes.
J Immunother Cancer. 2020 Aug;8(2):e000946. doi: 10.1136/jitc-2020-000946.PMID: 32759236
IF 10.252

84 Mezi S, Pomati G, Botticelli A, De Felice F, Musio D, Della Monaca M, Amirhassankhani S, Vullo F, Cerbelli B, Carletti R, Di Gioia C, Catalano C, Valentini V, Tombolini V, Della Rocca C, Marchetti P.Primary squamous cell carcinoma of major salivary gland: "Sapienza Head and Neck Unit" clinical recommendations. Rare Tumors. 2020 Nov 24;12:2036361320973526. doi: 10.1177/2036361320973526. eCollection 2020.PMID: 33282162

85 Cortellini A, Buti S, Bersanelli M, Giusti R, Perrone F, Di Marino P, Tinari N, De Tursi M, Grassadonia A, Cannita K, Tessitore A, Zoratto F, Veltri E, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Cappellini GCA, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Gelibter A, Occhipinti MA, Martella F, Inno A, Gori S, Bracarda S, Zannori C, Mosillo C, Parisi A, Porzio G, Mallardo D, Fargnoli MC, Tiseo M, Santini D, Ascierto PA, Ficorella CEvaluating the role of FAMIlly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.
.Oncoimmunology. 2020 Jan 7;9(1):1710389. doi: 10.1080/2162402X.2019.1710389. eCollection 2020.PMID: 32002308
IF 5.869

86 Botticelli A, Mezi S, Pomati G, Sciattella P, Cerbelli B, Roberto M, Mammone G, Cirillo A, Cassano A, Di Dio C, Cortellini A, Pizzuti L, Ronzino G, Salati M, Vici P, Polimeni A, Merlano MC, Nuti M, Marchetti PThe Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial.
.Vaccines (Basel). 2020 Apr 20;8(2):191. doi: 10.3390/vaccines8020191.PMID: 32326034
IF 3.143

87 Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Pergolesi F, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Ferrari M, Vitale MG, Nicolardi L, Chiari R, Rijavec E, Nigro O, Tuzi A, De Tursi M, Di Marino P, Conforti F, Queirolo P, Bracarda S, Macrini S, Gori S, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Santoni M, Patruno L, Porzio G, Ficorella C, Pinato DJ, Ascierto PA, Cortellini AEEffect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
.Eur J Cancer. 2021 Jan;142:18-28. doi: 10.1016/j.ejca.2020.09.033. Epub 2020 Nov 16.PMID: 33212418
IF 7.275

88 Roberto M, Astone A, Botticelli A, Carbognin L, Cassano A, D'Auria G, Fabbri A, Fabi A, Gamucci T, Krasniqi E, Minelli M, Orlandi A, Pantano F, Paris I, Pizzuti L, Portarena I, Salesi N, Scagnoli S, Scavina P, Tonini G, Vici P, Marchetti PCDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives.
.Cancers (Basel). 2021 Jan 18;13(2):332. doi: 10.3390/cancers13020332.PMID: 33477469
IF 5.742

89 Botticelli A, Cirillo A, Pomati G, Cerbelli B, Scagnoli S, Roberto M, Gelibter A, Mammone G, Calandrella ML, Cerbelli E, Di Pietro FR, De Galitiis F, Lanzetta G, Cortesi E, Mezi S, Marchetti P.J The role of opioids in cancer response to immunotherapy.
Transl Med. 2021 Mar 23;19(1):119. doi: 10.1186/s12967-021-02784-8.PMID: 33757546
IF 4.124

90 Mezi S, Botticelli A, Pomati G, Cerbelli B, Scagnoli S, Amirhassankhani S, d'Amati G, Marchetti P Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer.Cancers (Basel). 2021 Mar 3;13(5):1080. doi: 10.3390/cancers13051080.PMID: 33802438 Review.
IF 5.742

91 Ceccarelli F, Botticelli A, Natalucci F, Olivieri G, Cirillo A, Alessandri C, Marchetti P, Conti F Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view. Clin Transl Oncol. 2021 Mar 17. doi: 10.1007/s12094-021-02584-y. Online ahead of print.PMID: 33728870 No abstract available.
IF 2.737

92 Marchetti, P., Antonov, A., Anemona, L., Botticelli A., Mauriello A, Melino G., Catani, M.V.New

ABSTRACT AND POSTER

Poster AIOM 2011, Supplementi di Tumori Volume 11 number 2 october 2011 SNPs and docetaxel response in advanced breast cancer De Iuliis F., Russo I., Di Trapani M.C., Botticelli A., Gentile G, Simmaco M, Trasatto L. Roselli A., Pellegrini, P., Marchetti P

Poster attualità in senologia 2011: valutazione farmacogenomica della mieloe neurotossicità da taxani nelle pazienti affette da carcinoma mammario. Francesca De Iuliis, Maria Cristina Di Trapani, Ivana Russo, Andrea Botticelli, Arianna Roselli, Luciana trasatti, Marzia Lo Russo, Valeria Vitale, Laura Bersigotti, Gianni Lazzarin, Patrizia Pellegrini, Paolo Marchetti

Poster SIOMMS 2012 ADERENZA E TOLLERABILITA' DELL'ACIDO ZOLEDRONICO IN PAZIENTI ANZIANE CON TUMORE DELLA MAMMELLA IN TERAPIA CON INIBITORI DELL'AROMATASIA. Devito, R. Benvenuto, P. Pellegrini, L. Trasatti, A. Botticelli, E. De Marinis, I. Indiano, L. Tafaro, P. Falaschi. UO Geriatria, Azienda Ospedaliera S. Andrea Facoltà di Medicina e Psicologia, Sapienza Università di Roma

Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli ECPC-012 An Italian Cost-Effectiveness Analysis of Paclitaxel Albumin (Nab-Paclitaxel) Vs. Conventional Paclitaxel For Metastatic Breast Cancer Patients: The COSTANZA Study *European Journal of Hospital Pharmacy: Science and Practice* 20 (Suppl)20131 <http://dx.doi.org/10.1136/ejpharm-2013-000276.469>

Poster EBCC 2013 N 476 poster board 068 FcyR and FGFR4 polymorphisms associated with the pathological complete response (pCR) to trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. A. Botticelli, F. Mazzuca, M. La Torre, G. Gentile, P. Pellegrini, C. Maddalena, V. Sgroi, V. Ziparo, M. Simmaco, P. Marchetti

670PF. Mazzuca (Roma, Italy) A. Botticelli (Roma, Italy) L. Lionetto (Roma, Italy) M. La Torre (Roma, Italy) R. Giusti (Roma, Italy) C. Maddalena (Roma, Italy) P. Pellegrini (Roma, Italy) G. Gentile (Roma, Italy) F. Ciabatta (Roma, Italy) M. Borro (Roma, Italy) V. Ziparo (Roma, Italy) M. Simmaco (Roma, Italy) P. Marchetti (Roma, Italy) - Effect of degradation rate of 5-FU and genetic polymorphisms of DPD, TSER and MTHFR on toxicity and survival of 5-FU-based chemotherapy in gastric cancer *Ann Oncol* (2014) 25 (suppl_4): iv228. DOI: <https://doi.org/10.1093/annonc/mdu334.55> Published: 01 September 2014

AIOM2014 Effect of Degradation Rate of 5-FU and Genetic Polymorphisms of DPYD, TSER and MTHFR on Toxicity and Survival of 5-FU-based Chemotherapy in Metastatic Colorectal Cancer. Botticelli A., Mazzuca F., Maddalena C., La Torre M., Pellegrini P., Gentile G., Giusti R., Ciabatta F., Lionetto L., Borro M., Ziparo V., Simmaco M., Marchetti P.

AIOM2014 FcyR and FGFR4 polymorphisms related to Progression Free Survival in metastatic breast cancer patients treated with trastuzumab-based therapy Mazzuca F., Botticelli A., Maddalena C., La Torre M., Pellegrini P., Gentile G., Ciabatta F. R., Lionetto L., Borro M., Ziparo V., Simmaco M., Marchetti P.

Effect of degradation rate of 5-FU and genetic polymorphisms of DPYD, TSER and MTHFR on toxicity of capecitabine in colorectal cancer. Botticelli Andrea, Mazzuca Federica, Mazzotti Eva, Maddalena Chiara, Gentile Giovanna, Luana Lionetto, Marina Borro, Simmaco Maurizio, Marchetti Paolo. *European Journal of cancer* 2015,51, SUPPL 3 DOI 10.1016/S0959-8049(16)31091-7

Botticelli Andrea, Mazzuca Federica, Mazzotti Eva, Di Girolamo Marco, Carbonetti Francesco, Casazza Ines, Luana Lionetto, Gentile Giovanna, Marina Borro, Simmaco Maurizio, Marchetti Paolo Sarcopenia and toxicities in patients affected by breast cancer in adjuvant treatment *SABCS 2015*

P-0395- Michela Roberto, Adriana Romiti, Luana Lionetto, Chiara D'Antonio, Concetta Onesti, Andrea Botticelli, Annalisa Milano, Rosa Falcone, Mario Occhipinti, Federica Mazzuca, Maurizio Simmaco, Paolo Marchetti Fluorouracil Degradation Rate in Patients with Recurrent Gastrointestinal Cancer Treated with Metronomic Capecitabine Article in *Annals of Oncology* 27(suppl 2) June 2016 DOI: 10.1093/annonc/mdw199.37

M. Roberto A. Romiti A. Botticelli F.R. Di Pietro L. Lionetto G. Gentile F. Mazzuca R. Falcone M. Occhipinti S. Macrini E. Anselmi A. Petremolo C.E. Onesti M. Simmaco P. Marchetti 5-fluorouracil degradation rate as a predictive toxicity biomarker in early stage gastrointestinal cancer *Ann Oncol* (2016) 27 (suppl_6): 100P. DOI: <https://doi.org/10.1093/annonc/mdw363.48>

C.E. Onesti A. Botticelli F. Mazzuca S. Angelini A. Petremolo R. Falcone M. Roberto M. Occhipinti A. Romiti L. Lionetto M. Simmaco P. Marchetti 5-fluorouracil degradation rate (5-FU-DR) could predict toxicity in breast cancer patients treated with capecitabine *Ann Oncol* (2016) 27 (suppl_4): iv68. DOI: <https://doi.org/10.1093/annonc/mdw337.29> Published: 21 September 2016

C.E. Onesti A. Botticelli F. Mazzuca A. Milano A. Romiti M. Roberto R. Falcone M. Occhipinti F.R. Di Pietro L. Lionetto M. Simmaco P. Marchetti

5-fluorouracil degradation rate (5-FU-DR) as a new toxicity predictive biomarker for adjuvant FOLFOX in colorectal cancer (CRC) patients *Ann Oncol* (2016) 27 (suppl_6): 586P. DOI: <https://doi.org/10.1093/annonc/mdw370.134> Published: 11 October 2016

M Occhipinti, A Botticelli, CE Onesti, M Ghidini, R Righini, C Pizzo, A Milano, G Tomasello, FR Di Pietro, L Toppo, M Ratti, R Passalacqua, P Marchetti, F Mazzuca D23 Treatment and outcome for small bowel adenocarcinoma (SBA): a real life experience of two Italian centres *Annals of Oncology* 28(suppl_6) October 2017 DOI 10.1093/annonc/mdx425.022

L Mentuccia, A Gelibter, I Sperduti, L D'onofrio, A Botticelli, P Vici, A Cassano, L Moschetti, L Carbognin, V Graziano, G Barchiesi, E Rossi, MC Cursano, L Pizzuti, I Paris, A Vaccaro, A Fabbri, L Rossi, R Samaritani, R Sarmiento, T Gamucci C5 Efficacy of pertuzumab in combination with trastuzumab and a taxane in first line treatment for metastatic breast cancer (MBC): a multicenter retrospective observational study *Annals of Oncology* 35 (15_suppl), e12504-e12504 2017

A Botticelli, B Cerbelli, A Pernazza, CE Onesti, P Sciattella, L Costarelli, M Monti, D Campagna, F Mazzuca, L Fortunato, P Marchetti, G D'Amati 111 PPD-L1 expression in

TNBC: A predictive biomarker of response to neoadjuvant chemotherapy? *Annals of Oncology* September 2017 (Supl_5) DO 10.1093/annonc/mdx363.027

Michele Ghidini, Andrea Botticelli, Bianca Maria Donida, Lidia Strigari, Concetta Elisa Onesti, Margherita Ratti, Claudio Pizzo, Federico Aldighieri, Laura Toppo, Valerio Ranieri, Mario Occhipinti, Chiara Senti, Giulia Tanzi, Federica Mazzuca, Paolo Marchetti, Mario Martinotti, Rodolfo Passalacqua, Gianluca Tomasello, Massimo Rovatti Prognostic factors associated with survival and recurrence in resectable gastroesophageal adenocarcinoma: retrospective analysis of 497 patients operated at two Italian centers *Journal of Clinical Oncology* 35 (15_suppl), e15588-e15588 2017

Laura Toppo, Wanda Liguigli, Chiara Senti, Gianluca Tomasello, Michele Ghidini, Margherita Ratti, Andrea Botticelli, Concetta Elisa Onesti, Francesca Di Pietro, Claudio Pizzo, Stefano Panni, Alessandra Curti, Rodolfo Passalacqua Presence of bone metastases (BM) at diagnosis is associated with poor prognosis and coagulation disorders (CD) in patients (pts) with advanced gastric cancer (AGC) *Journal of Clinical Oncology* 35 (15_suppl), e15538-e15538 2017

Marianna Nuti, Ilaria Zizzari, Chiara Napoletano, Andrea Botticelli, Fabio Calabro, Alain Gelibter, Aurelia Rughetti, Alessio Ugolini, Ilary Ruscito, Federica Mazzuca, Hassan Rahimi, Concetta Elisa Onesti, Enrico Cortesi, Paolo Marchetti Immunomodulatory effects of tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) patients. *Journal of Clinical Oncology* 35 (15_suppl), e14506-e14506 2017

CE Onesti, A Botticelli, M Occhipinti, FR Di Pietro, I Zizzari, C Napoletano, M Nuti, S Lauro, F Mazzuca, P Marchetti 118PEarly onset of endocrine alterations during PD-1 blockade in advanced NSCLC patients *Annals of Oncology* 28 (suppl_2) 2017

Anatomic site of metastases can influence response to nivolumab in NSCLC patients. A Botticelli, B Cerbelli, P Sciattella, M Salati, I Zizzari, M Roberto, G Poti, Federica De Galitiis, Vincenzo Picone, Giulia D'Amati, Federica Mazzuca, Marianna Nuti, Paolo Marchetti *Journal of Clinical Oncology* 36 (15_suppl), e15021-e15021

Effect of nutritional support with highly purified, whey proteins for malnutrition and sarcopenia in patients affected with stage II-III colorectal or breast cancer: A blind, F Mazzuca, M Roberto, A Botticelli, L Marchetti, E Sarfati, E Crimini, Francesca Schipilliti, Marco Di Girolamo, Maurizio Muscaritoli, Paolo Marchetti *Journal of Clinical Oncology* 36 (15_suppl), TPS10129-TPS10129

Changes of microbiome profile during nivolumab treatment in NSCLC patients. A Botticelli, L Putignani, I Zizzari, F Del Chierico, S Reddel, F Di Pietro, Andrea Quagliarello, Concetta Elisa Onesti, Giusti Raffaele, Federica Mazzuca, Marianna Nuti, Paolo Marchetti *Journal of Clinical Oncology* 36 (15_suppl), e15020-e15020

The key role of kynurenine in antiPD-1 failure A Botticelli, B Cerbelli, L Lionetto, I Zizzari, A Pisano, M Roberto, Michela Roberto, Concetta Elisa ONESTI, Francesca Di Pietro, Chiara Napoletano, Laura Pizzuti, Patrizia Vici, Giulia D'Amati, Federica Mazzuca, Maurizio Simmaco, Patrizia Nuti, Paolo Marchetti AACR 2018

PARTECIPAZIONE A CONGRESSI NAZIONALI E INTERNAZIONALI

PARTECIPAZIONE A NUMEROSI CONGRESSI NAZIONALI E INTERNAZIONALI

24.2.2016 RESPONSABILE SCIENTIFICO : La malattia oligometastatica. Passato, presente , futuro Roma RESPONSABILE SCIENTIFICO

17-06-2016 RELATORE IncontrAIOM : IL SALOTTO DI AIOM REGIONE LAZIO , IMMUNOLOGIA ETUMORI MALATTIE A CONFRONTO , POLICLINICO UMBERTO I ROMA 17.06.2016

15-16 luglio 2016 RELATORE MASTER COURSE IMI : MANAGEMENT DEL PAZIENTE CON MELANOMA : DALLA RICERCA ALLA TERAPIA ,IDI, ROMA

22.10.2016 RELATORE HOT TOPICS IN ONCOLOGIA 2016 FIUGGI FR

27.01.2017 RELATORE CONGRESSO AIOM BREAKING NEWS FROM SAN ANTONIO (AIOM),POLICLINICO UMBERTO I Roma,

25-05-2017 RELATORE 3 SURVEY INTERREGIONALE PER LA DETERMINAZIONE DI HER2 VALUTAZIONE SU AGOBIOPSIA ED ESPERIENZE A CONFRONTO SU PAZIENTE IN PRIMA LINEA METASTATICA ROMA

14-06-2017RELATORE HELPDESK IN Mrcc : SHARE THE CLINICAL EXPERIENCE ROMA

22.6.2017RELATORE CONGRESSO AIOM LAZIO OLTRE LO STUDIO CLINICO : IL CARCINOMA MAMMARIO NEL REAL WORLD ROMA

4.7.2017 RELATORE CARCINOMA MAMMARIO METASTATICO : STATO DELL'ARTE ROMA

22-23.09.2017 RELATORE YOUNGS IN BREAST ESPERIENZE A CONFRONTO MONTE PORZIO CATONE

6-7.10.2017 RELATORE THE BEST OF THE YEAR MEETS THE FIRST POST ESMO

13.-14.10.2017SEGRETERIA SCIENTIFICA IL CARCINOMA MAMMARIO AL TEMPO DELLA MEDICINA DI PRECISIONE ROMA

29.1.2018 RELATORE CONGRESSO AIOM LAZIO POST SAN ANTONIO ROMA AIOM

11-12 MAGGIO 2018RELATORE LA NEOPLASIA MAMMARIA AL TEMPO DELLA MEDICINA DI PRECISIONE ROMA

13.6.2018 RELATORE CARCINOMA MAMMARIO HER2 POSITIVO IN FASE METASTATICA ROMA

21-06-2018RELATORE NEOPLASIE RENALI 2.0 DALLE LINEE GUIDA ALLA PRATICA CLINICA ROMA

2 LUGLIO 2018 RELATORE CONGRESSO AIOM LAZIO LA METODOLOGIA DENTRO LA CLINICA ROMA AIOM

04-07-2018 al 05-07-2018RELATORE EDUCATIONAL COURSE : SHARE THE EXPERIENCE : L'IMMUNOTERAPIA ROMA

21-09-2018 al 22-09-2018RELATORE CONGRESSO AIOM -INTERREGIONALE POLMONE 21-22 SETT 2018

ROMA

11-13.10.2018 RELATORE CONGRESSO INTERNAZIONALE XVI NIBIT MEETING MILANO
dal 11-10-2018 al 13-10-2018

31-10-2018 RELATORE NUTRIZIONE E NUTRACEUTICA IN ONCOLOGIA MESTRE

16-17-18-11.2018 RELATORE XX AIOM NAZIONALE

11.12.2018 RELATORE TARGET THERAPY ROMA

13-12-2018 RELATORE CONGRESSO UBI MAIOR MINOR DOCET ROMA

19.12.2018 RELATORE CONGRESSO AIOM LAZIO THE BEST OF THE YEAR 2018 , AIOM, ROMA

05-04-2019 al 06-04-2019 RELATORE Nivolution, livearound sessione 5 : looking toward the future.
Relazione : Progetto Yo-IO

17 APRILE 2019 RELATORE AGGIORNAMENTI IN ONCOLOGIA : LA RIVOLUZIONE NEL TUMORE DEL
POLMONE _ IMMUNOTERAPIA SAN GIOVANI CALIBITA ROMA

17 maggio 2019 MODERATORE CONGRESSO AIOM LAZIO Biosimilari in Oncologia : OPPORTUNITÀ E
CRITICITÀ (AIOM) Roma

17-05-2019 al 18-05-2019 SEGRETERIA SCIENTIFICA CONGRESSO INTERNAZIONALE Implementing Precision
Medicine in cancer care – May, 17th 18th 2019 ROME

21.6.2019 SEGRETERIA SCIENTIFICA WORKSHOP: IMMUNOONCOLOGIA NEL TUMORE DEL POLMONE,
ROMA

4 LUGLIO 2019 RELATORE IL CARCINOMA MAMMARIO TRATTAMENTI INDIVIDUALIZZATI E QUALITÀ DI
VITA ROMA

09-07-2019 RELATORE Le cure simultanee oncoematologiche : passato- presente e futuro 9.07.2019 Roma

17-09-2019 RELATORE Gestione della paziente metastatica HT+ in trattamento con CDK4/6i 17.09.2019
Roma

8-9.10.2019 RELATORE E SEGRETERIA SCIENTIFICA I-GRANDANGOLO FOCUS IN IMMUNO_ONCOLOGIA :
roma

25-26-27-10.2019 MODERATORE XXI AIOM NAZIONALE Roma

08-11-2019 RELATORE E SEGRETERIA SCIENTIFICA 2° workshop : neoplasie renali 3.0 Roma

15.11.2019 RELATORE Torre di Babele : il team in immunooncologia Roma

21 -11-2019 MODERATORE Carcinoma Mammario Non luminal Roma

27.11.2019 RELATORE BUSSULA: breast unit symposium of Sardegna, Umbria, Lazio e Abruzzo Roma

28-29 novembre 2019 RELATORE Learning at th leaning tower 2019 Gono congress on colorectal cancer
Pisa

2-3 dic 2019 RELATORE CONGRESSO AIOM LAZIO POST ESMO from Barcelona to Real World AIOM :
relatore e comitato scientifico

06-12-2019 al 07-12-2019 SEGRETERIA SCIENTIFICABRCA tra presente e future Roma ,

09-12-2019 SEGRETERIA SCIENTIFICA : CASI DIFFICILI IN IMMUNOONCOLOGIA ROMA

20.5.2020 RELATORE PRESSO "CONSENSUS LAZIALE SUL TRATTAMENTO DEL CARCINOMA MAMMARIO HR+
IN FASE AVANZATA" WEBINAR

7.10.2020 RELATORE E RESPONSABILE SCIENTIFICO ROMA, CONGRESSO LE NUOVE FRONTIERE NEI TUMORI
DELLA TESTA E DEL COLLO WEBINAR

20.11.2020 RELATORE CONGRESSO PROGETTO LA FARMACOGENOMICA APPLICATA NEL TRATTAMENTO
DELL'ABC . WEBINAR

26.10.2020 RELATORE DIAGNOSI E TRATTAMENTO MULTIDISCIPLINARE DEI TUMORI DEL DISTRETTO
TESTA COLLO WEBINAR

7.11.2020 RELATORE PROGETTO IL TRATTAMENTO DELLA PAZIENTE MBC HR+ E HER2- WEBINAR

24.11.2020 RELATORE CONGRESSO YO BREAST – YOUNG ONCOLOGISTS IN BREAST CANCER WEBINAR

25.11.2020 CONGRESSO TORRE DI BABEL2.0: IL TEAM DI IMMUNO-ONCOLOGIA. WEBINAR
1.12.2020 RELATORE CONGRESSO CONGRESSO BREASTART WEBINAR
9.12.2020 RELATORE E RESPONSABILE SCIENTIFICO CASI DIFFICILI IN IMMUNOONCOLOGIA WEBINAR
14.1.2021 RELATORE PRESSO CONGRESSO I-GRANDANGOLO WEBINAR
20.1.2021 RELATORE Il trattamento multidisciplinare dei tumori del distretto testa-collo: un approccio pratico", WEBINAR
17.2.2021 RELATORE AIOM LAZIO POST SABCS WEBINAR
26.2.2021 RELATORE 'Incontriamoci sul Pink Ring 2.0 webinar dal titolo 'VACCINAZIONE anti-SARS-CoV-2/COVID-19 NEI PAZIENTI ONCOLOGICI'
30.3.2021 RELATORE Young Conversation: Il trattamento della paziente con MBC HER2-/HR+ NELLA PRATICA CLINICA WEBINAR
17.3.2021 RELATORE AIOM I MERCOLEDÌ DELL'ONCOLOGIA - IL MICROBIOTA: UNA NUOVA FRONTIERA IN ONCOLOGIA WEBINAR
18.3.2021 RELATORE E SEGRETERIA SCIENTIFICA : BREAST TALENT 2.0 WEBINAR

Rome, 12th April 2021

Audrea Bertucci